Abstract
Introduction
We compared the rates of long-term adjuvant endocrine therapy (AET) adherence after
various radiation therapy (RT) modalities among patients with early stage breast cancer.
Materials and Methods
Medical records from patients with stage 0, I, or IIA (tumors ≤3 cm), hormone receptor
(HR) positive breast cancer that received adjuvant radiation therapy (RT) from 2013
to 2015 at a single institution were retrospectively reviewed. All patients received
breast conserving surgery (BCS) followed by adjuvant RT via one of the following modalities:
whole breast radiotherapy (WBI), partial breast irradiation (PBI) with either external
beam radiation therapy (EBRT) or fractionated intracavitary high-dose rate (HDR) brachytherapy,
or single fraction HDR-brachytherapy intraoperative-radiation therapy (IORT).
Results
One hundred fourteen patients were reviewed. Thirty patients received WBI, 41 PBI,
and 43 IORT with a median follow up of 64.2, 72.0, and 58.6 months, respectively.
For the entire cohort, AET adherence was approximately 64% at 2 years and 56% at 5
years. Among patients in the IORT clinical trial, adherence to AET was approximately
51% at 2 years and 40% at 5 years. After controlling for additional factors, DCIS
histology (vs invasive disease) and IORT (compared to other radiation modalities)
were associated with decreased endocrine therapy adherence (P < 0.05).
Conclusion
DCIS histology and receipt of IORT were associated with lower rates of adherence to
AET at 5 years. Our findings suggest that examination of the efficacy of RT interventions
such as PBI and IORT in patients who do not receive AET is warranted.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials.Lancet. 2011; 378: 771-784
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials.Lancet. 2005; 365: 1687-1717
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial.Lancet. 2013; 381: 805-816
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.Lancet Oncol. 2010; 11: 1135-1141
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.Lancet Oncol. 2008; 9: 45-53
- Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.J Clin Oncol. 2010; 28: 509-518
- Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.Breast Cancer Res Treat. 2008; 107: 167-180
- American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.J Clin Oncol. 2010; 28: 3784-3796
- Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.J Clin Oncol. 2008; 26: 556-562
- Early Discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women.Clin Cancer Res. 2021; 27: 1421-1428
Goldberg M., Sutradhar R., Paszat L., et al. Abstract P5-12-06: Non-adherence to endocrine therapy is associated with a significant increased risk of local recurrence in women ≥65 years with stage T1N0 breast cancer treated with adjuvant endocrine therapy alone after breast-conserving surgery. Cancer Res. 2020;80(4 Supplement). p. P5-12-06-P5-12-06.
- Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).Int J Radiat Oncol Biol Phys. 2009; 74: 987-1001
- Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.Lancet. 2019; 394: 2155-2164
- Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-florence trial.J Clin Oncol. 2020; 38: 4175-4183
- Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomized, non-inferiority phase 3 trial.Lancet. 2010; 376: 91-102
- Intraoperative radiotherapy for early breast cancer - insufficient evidence to change practice.Nat Rev Clin Oncol. 2020; 17: 723-724
- Implementation of an HDR brachytherapy-based breast IORT program: initial experiences.Brachytherapy. 2019; 18: 285-291
- An examination of nationwide trends in accelerated partial breast irradiation - The replacement of breast brachytherapy with intraoperative radiotherapy and external beam radiation.Radiother Oncol. 2022; 166: 79-87
- Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.J Clin Oncol. 2010; 28: 4120-4128
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer.Br J Cancer. 2008; 99: 1763-1768
- A novel form of breast intraoperative radiation therapy with CT-guided high-dose-rate brachytherapy: results of a prospective phase 1 clinical trial.Int J Radiat Oncol Biol Phys. 2016; 96: 46-54
- Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.N Engl J Med. 2004; 350: 1937-1944
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.Lancet Oncol. 2015; 16: 266-273
- Lumpectomy plus Tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.N Engl J Med. 2004; 351: 971-977
- Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.Cancer. 2019; 125: 3266-3274
- Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.Lancet. 2014; 383: 603-613
- Long-term results of hypofractionated radiation therapy for breast cancer.N Engl J Med. 2010; 362: 513-520
- START Trialists’ Group; Bentzen S.M., Agrawal R.K., Aird E.G., et al. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.Lancet. 2008; 371: 1098-1107
- Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement.Pract Radiat Oncol. 2017; 7: 73-79
- Comparing hypofractionated with conventional fractionated radiotherapy after breast-conserving surgery for early breast cancer: a meta-analysis of randomized controlled trials.Front Oncol. 2021; 11: 753209
- Changing practice patterns of adjuvant radiation among elderly women with early stage breast cancer in the United States from 2004 to 2014.Breast J. 2020; 26: 353-367
- Fractionation trends in breast cancer and implications in partial breast irradiation.Brachytherapy. 2017; 16: S52-S53
- External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.Lancet. 2019; 394: 2165-2172
- Evaluating the long-term impact of a cooperative group trial on radiation use and adjuvant endocrine therapy adherence among older women.Ann Surg Oncol. 2020; 27: 3458-3465
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.Lancet. 2011; 378: 1707-1716
- Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer.N Engl J Med. 2004; 351: 963-970
- Mortality impact of less-than-standard therapy in older breast cancer patients.J Am Coll Surg. 2008; 206: 66-75
- Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.J Clin Oncol. 2007; 25: 1683-1690
- Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.Breast Cancer Res Treat. 2020; 184: 805-816
- Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.BMC Cancer. 2013; 13: 401
- Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer.J Clin Oncol. 2002; 20: 2680-2688
- Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers.Breast Cancer Res Treat. 2017; 165: 247-260
- Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review.Clin J Oncol Nurs. 2014; 18: E50-E57
- Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.Cancer. 2017; 123: 169-176
- Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer.J Clin Oncol. 2004; 22: 3309-3315
Article info
Publication history
Published online: January 31, 2023
Accepted:
January 25,
2023
Received in revised form:
December 24,
2022
Received:
July 28,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
